The
report analyzes and presents an overview of " Hepatitis C Global
Clinical Trials Review, H2, 2016 " worldwide.
GlobalData's clinical trial
report, Hepatitis
C Global
Clinical Trials Review, H2, 2016" provides an overview of
Hepatitis C clinical trials scenario. This report provides top line
data relating to the clinical trials on Hepatitis C. Report includes
an overview of trial numbers and their average enrollment in top
countries conducted across the globe. The report offers coverage of
disease clinical trials by region, country (G7 & E7), phase,
trial status, end points status and sponsor type. Report also
provides prominent drugs for in-progress trials (based on number of
ongoing trials). GlobalData Clinical Trial Reports are generated
using GlobalDatas proprietary database - Pharma eTrack Clinical
trials database. Clinical trials are collated from 80+ different
clinical trial registries, conferences, journals, news etc across the
globe. Clinical trials database undergoes periodic update by dynamic
process.
The report enhances the
decision making capabilities and helps to create an effective counter
strategies to gain competitive advantage.
Download
Sample copy of this Report @
Scope
-
The report provides a snapshot of the global clinical trials
landscape
-
Report provides top level data related to the clinical trials by
Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor
Type and End point status
-
The report reviews top companies involved and enlists all trials
(Trial title, Phase, and Status) pertaining to the company
-
The report provides all the unaccomplished trials (Terminated,
Suspended and Withdrawn) with reason for unaccomplishment
-
The Report provides enrollment trends for the past five years
-
Report provides latest news for the past three months
Reasons
to buy
-
Assists in formulating key business strategies with regards to
investment
-
Helps in identifying prominent locations for conducting clinical
trials which saves time and cost
-
Provides top level analysis of Global Clinical Trials Market which
helps in identifying key business opportunities
-
Supports understanding of trials count and enrollment trends by
country in global therapeutics market
-
Aids in interpreting the success rates of clinical trials by
providing a comparative scenario of completed and uncompleted
(terminated, suspended or withdrawn) trials
-
Facilitates clinical trial assessment of the indication on a global,
regional and country level
Table
of Content :
Table
of Contents 2
List
of Tables 3
List
of Figures 4
Report
Guidance 5
Clinical
Trials by Region 6
Clinical
Trials and Average Enrollment by Country 7
Top
Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top
Five Countries Contributing to Clinical Trials in Europe 10
Top
Countries Contributing to Clinical Trials in North America 11
Top
Five Countries Contributing to Clinical Trials in Middle East and
Africa 12
Top
Five Countries Contributing to Clinical Trials in Central and South
America 13
Clinical
Trials by G7 Countries: Proportion of Hepatitis C to Infectious
Disease Clinical Trials 14
Clinical
Trials by Phase in G7 Countries 15
Clinical
Trials in G7 Countries by Trial Status 16
Clinical
Trials by E7 Countries: Proportion of Hepatitis C to Infectious
Disease Clinical Trials 17
Clinical
Trials by Phase in E7 Countries 18
Clinical
Trials in E7 Countries by Trial Status 19
Clinical
Trials by Phase 20
In
Progress Trials by Phase 21
Clinical
Trials by Trial Status 22
Clinical
Trials by End Point Status 23
Subjects
Recruited Over a Period of Time 24
Clinical
Trials by Sponsor Type 25
Prominent
Sponsors 26
Top
Companies Participating in Hepatitis C Therapeutics Clinical Trials
27
Prominent
Drugs 28
Latest
Clinical Trials News on Hepatitis C 29
Aug
11, 2016: New Interim Phase IIa Data on Simeprevir in Combination
with Other DAAs Will Be Presented at the Upcoming EASL AASLD Special
Conference 29
Aug
08, 2016: Results from Merck's Phase 3 Study Evaluating ZEPATIER
(elbasvir and grazoprevir) in Patients with Chronic Hepatitis C
Receiving Treatment for Opioid Dependence Published in Annals of
Internal Medicine 29
Jun
21, 2016: Trek Therapeutics Initiates Phase 2a Study of Faldaprevir
and TD-6450, With and Without Ribavirin, in Patients with HCV GT 1b
30
Jun
21, 2016: Ascletis Publishes Interim Data of Phase II Study in Taiwan
for its Interferon-free HCV Regimen 30
Jun
20, 2016: Enanta Pharmaceuticals Initiates Proof-of-Concept Study
with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with
Genotype 1 or Genotype 3 Chronic Hepatitis C Virus 30
Jun
07, 2016: Regulus Reports Positive Top-line Data 32
Clinical
Trial Profile Snapshots 33
Appendix
1744
Abbreviations
1744
Definitions
1744
Research
Methodology 1745
Secondary
Research 1745
About
GlobalData 1746
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
us:
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA:
Canada Toll Free: 866-997-4948
No comments:
Post a Comment